Literature DB >> 24476819

Cancer: interference identifies immune modulators.

Lars Zender1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24476819     DOI: 10.1038/nature13050

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

3.  A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration.

Authors:  Torsten Wuestefeld; Marina Pesic; Ramona Rudalska; Daniel Dauch; Thomas Longerich; Tae-Won Kang; Tetyana Yevsa; Florian Heinzmann; Lisa Hoenicke; Anja Hohmeyer; Anna Potapova; Ina Rittelmeier; Michael Jarek; Robert Geffers; Maren Scharfe; Frank Klawonn; Peter Schirmacher; Nisar P Malek; Michael Ott; Alfred Nordheim; Arndt Vogel; Michael P Manns; Lars Zender
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  In vivo discovery of immunotherapy targets in the tumour microenvironment.

Authors:  Penghui Zhou; Donald R Shaffer; Diana A Alvarez Arias; Yukoh Nakazaki; Wouter Pos; Alexis J Torres; Viviana Cremasco; Stephanie K Dougan; Glenn S Cowley; Kutlu Elpek; Jennifer Brogdon; John Lamb; Shannon J Turley; Hidde L Ploegh; David E Root; J Christopher Love; Glenn Dranoff; Nir Hacohen; Harvey Cantor; Kai W Wucherpfennig
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

7.  An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.

Authors:  Lars Zender; Wen Xue; Johannes Zuber; Camile P Semighini; Alexander Krasnitz; Beicong Ma; Peggy Zender; Stefan Kubicka; John M Luk; Peter Schirmacher; W Richard McCombie; Michael Wigler; James Hicks; Gregory J Hannon; Scott Powers; Scott W Lowe
Journal:  Cell       Date:  2008-11-13       Impact factor: 41.582

8.  Lipid phosphatases identified by screening a mouse phosphatase shRNA library regulate T-cell differentiation and protein kinase B AKT signaling.

Authors:  Liying Guo; Craig Martens; Daniel Bruno; Stephen F Porcella; Hidehiro Yamane; Stephane M Caucheteux; Jinfang Zhu; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

9.  Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model.

Authors:  Anka Bric; Cornelius Miething; Carl Uli Bialucha; Claudio Scuoppo; Lars Zender; Alexander Krasnitz; Zhenyu Xuan; Johannes Zuber; Michael Wigler; James Hicks; Richard W McCombie; Michael T Hemann; Gregory J Hannon; Scott Powers; Scott W Lowe
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.

Authors:  Corbin E Meacham; Emily E Ho; Esther Dubrovsky; Frank B Gertler; Michael T Hemann
Journal:  Nat Genet       Date:  2009-09-27       Impact factor: 38.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.